SEC Form 4 · accession 0001106578-26-000083
UNITED THERAPEUTICS Corp · UTHR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Martine A Rothblatt
Officer — Chairperson & CEO · Director
Period of report
Jun 22, 2026
Accepted (ET)
Jun 24, 2026 · 8:47 am EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001082554
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 22, 2026 | M | 6,590 | $135.42 | A | 47,103 | D | |
| Common Stock | Jun 22, 2026 | M | 2,910 | $146.03 | A | 50,013 | D | |
| Common StockF2 | Jun 22, 2026 | S | 232 | $534.0871 | D | 49,781 | D | |
| Common StockF3 | Jun 22, 2026 | S | 995 | $534.9414 | D | 48,786 | D | |
| Common StockF4 | Jun 22, 2026 | S | 1,133 | $536.0198 | D | 47,653 | D | |
| Common StockF5 | Jun 22, 2026 | S | 1,000 | $537.1302 | D | 46,653 | D | |
| Common StockF6 | Jun 22, 2026 | S | 3,198 | $538.2867 | D | 43,455 | D | |
| Common StockF7 | Jun 22, 2026 | S | 2,671 | $539.1829 | D | 40,784 | D | |
| Common StockF8 | Jun 22, 2026 | S | 271 | $539.9008 | D | 40,513 | D | |
| Common Stock | holding | — | — | — | 166 | I | by Spouse | |
| Common StockF9 | holding | — | — | — | 324,443 | I | by Trust | |
| Common StockF10 | holding | — | — | — | 249,108 | I | by Trust | |
| Common StockF11 | holding | — | — | — | 45,596 | I | by Trust | |
| Common StockF12 | holding | — | — | — | 8,902 | I | by Trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option | $135.42 | Jun 22, 2026 | M | 6,590 | D | Mar 15, 2023 | Mar 15, 2027 | Common Stock | 6,590 | 144,218 | D |
| Stock Option | $146.03 | Jun 22, 2026 | M | 2,910 | D | Mar 15, 2020 | Mar 15, 2027 | Common Stock | 2,910 | 0 | D |
| Stock OptionF13 | $135.42 | holding | — | — | — | Mar 15, 2023 | Mar 15, 2027 | Common Stock | 349,192 | 349,192 | I |
Explanation of responses
- F1This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026.
- F10Shares held in family trusts as to which the Reporting Person's spouse is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.
- F11Shares held in family trusts as to which the Reporting Person's spouse shares investment power and the Reporting Person and/or immediate family members are beneficiaries.
- F12Shares held in family trusts as to which the Reporting Person is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.
- F13Stock options held in a family trust as to which the Reporting Person shares investment power and the Reporting Person and immediate family members are beneficiaries.
- F2This transaction was executed in multiple trades at prices ranging from $533.46 to $534.45. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F3This transaction was executed in multiple trades at prices ranging from $534.47 to $535.43. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F4This transaction was executed in multiple trades at prices ranging from $535.48 to $536.44. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F5This transaction was executed in multiple trades at prices ranging from $536.68 to $537.58. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F6This transaction was executed in multiple trades at prices ranging from $537.73 to $538.72. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F7This transaction was executed in multiple trades at prices ranging from $538.73 to $539.72. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F8This transaction was executed in multiple trades at prices ranging from $539.80 to $540.07. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F9Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries.